Active Ingredient(s): Gadobutrol
FDA Approved: * March 14, 2011
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Gadavist Overview

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States.[1][2][3][4] As of 2007, it was the only GBCA approved at 1.0 molar concentrations.[5] Gadobutrol is marketed by Bayer AG as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.[6] In India, it is also marketed by Vivere Imaging as Viv-butrol.&a...

Read more Gadavist Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Gadavist Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 1mmol/ml
  • Solution: 1.20944gm/2ml (604.72mg/ml), 18.1416gm/30ml (604.72mg/ml), 39.3068gm/65ml (604.72mg/ml), 4.5354gm/7.5ml (604.72mg/ml), 6.0472gm/10ml (604.72mg/ml), 9.0708gm/15ml (604.72mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Gadavist: (1 result)

Sorted by National Drug Code
  • 50419-325 Gadavist 604.72 mg/ml Intravenous Injection by Bayer Healthcare Pharmaceuticals Inc.

Other drugs which contain Gadobutrol or a similar ingredient: (1 result)